Key result
The fixed combination of lisinopril and indapamide offers potential advantages in the treatment of hypertension and optimization of cardioprotection, based on a review of clinical trials.
Why the study?
Does the fixed combination of lisinopril and indapamide improve cardioprotection in hypertensive patients?
Does the fixed combination of lisinopril and indapamide improve cardioprotection in hypertensive patients?
The review highlights the potential advantages of combining lisinopril and indapamide for cardioprotection and managing myocardial hypertrophy in hypertensive patients.
Should not yet alter hypertension practice; leaves open need for prospective RCTs on cardioprotection.
The article presents current knowledge of рro- and antihypertensive mechanisms involved in the development of hypertension (HTN), and antihypertensive management strategies. Particular attention is paid to the angiotensin converting enzyme inhibitor lisinopril and thiazide-like diuretic indapamide. The mechanisms and effects are described. The paper discusses the results of multicenter randomized clinical trials, and the antihypertensive effects of lisinopril and indapamide and their impact on myocardial hypertrophy in hypertensive patients. The potential advantages of fixed combination of lisinopril and indapamide in the treatment of patients with HTN are also discussed.
No takes yet. Share an insight, caveat, or question.
Подзолков et al. (2018) conducted a review in hypertension (HTN). Fixed combination of lisinopril and indapamide was evaluated. The fixed combination of lisinopril and indapamide offers potential advantages in the treatment of hypertension and optimization of cardioprotection, based on a review of clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: